| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 1,610,530 | 1,541,570 | 1,557,670 | 1,542,450 | 1,371,870 |
| Sales Growth | +4.47% | -1.03% | +0.99% | +12.43% | -9.60% |
| Net Income | -6,940 | 67,740 | 180,550 | 169,080 | 133,890 |
| Net Income Growth | -110.25% | -62.48% | +6.78% | +26.28% | +166.71% |
Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT). The CSS business offers global, market-leading technologies, brands and instrumentation. The global commercial network includes clinical specialists, a large direct global sales force and strategic partnerships and distributors that serve hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers and health care providers in North America, South America, Europe, Asia Pacific, Middle East and Africa. The Tissue Technologies segment includes wound reconstruction and repair products, bone grafts and nerve and tendon repair products.
Fiscal Year End Date: 12/31